Ledger has introduced a new feature in its wallet app allowing eligible users to borrow USDC or USDT stablecoins by pledging Bitcoin collateral in the form of cbBTC or wBTC. This decentralized borrowing service uses Morpho’s lending infrastructure and integrates hardware security via Ledger devices, requiring physical approval for transactions. The feature aims to let users access liquidity without selling their Bitcoin or using centralized platforms, with loan terms varying by market conditions and liquidation risks. The rollout will be gradual and country-dependent, complementing Ledger Earn, and includes a limited-edition Spurs hardware wallet release.
Ledger's new Bitcoin-backed loan feature is presented here with a snapshot of Pluang's cryptocurrency market as of Oct 07, 2026 01:12 WIB: Out of 50 major cryptocurrencies, 24 rose and 25 fell. Avalanche (AVAX) gained 5.73% to Rp206.356 with a buy-dominant order activity of 65%, contrasting with Theta Network (THETA) which dropped 4.13% to Rp1.834 but saw 74% buy orders, while Basic Attention Token (BAT) fell 4.13% to Rp1.834 with 26% sell orders. This shows mixed market dynamics among top tokens.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
Evercore ISI raised its price target for Marvell Technology to $433 from $275, maintaining an Outperform rating. This follows Marvell's optimistic revenue projections, expecting $20 billion by fiscal 2028 and $70-$90 billion by fiscal 2031, driven by...
